Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study

Blood

Volumn 93, Issue 7, 1999, Pages 2411-2419

  Reichardt, Volker L ^a   Okada, Craig Y ^a   Liso, Arcangelo ^a   Benike, Claudia J ^a   Stockerl Goldstein, Keith E ^a   Engleman, Edgar G ^a   Blume, Karl G ^a   Levy, Ronald ^a,b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN IDIOTYPE; IMMUNOLOGICAL ADJUVANT; KEYHOLE LIMPET HEMOCYANIN; MELPHALAN; PARAPROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG MEGADOSE; ERADICATION THERAPY; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; INTRAVENOUS DRUG ADMINISTRATION; LEUKAPHERESIS; LYMPHOCYTE PROLIFERATION; MALE; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION; WHOLE BODY RADIATION;

EID: 0033120389     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.7.2411     Document Type: Article

References (42)

1. Sirisinha S, Eisen HN: Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. Proc Natl Acad Sci USA 68:3130, 1971
2. Lynch RG, Graff RJ, Sirisinha S, Simms ES, Eisen HN: Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci USA 69:1540, 1972
3. Croese JW, Vissinga CS, Boersma WJ, Radl J: Immune regulation of mouse 5T2 multiple myeloma. 1. Immune response to 5T2 MM idiotype. Neoplasma 38:457, 1991
4. Croese JW, Van den Enden-Vieveen MH, Radl J: Immune regulation of 5T2 mouse multiple myeloma. II. Immunological treatment of 5T2 MM residual disease. Neoplasma 38:467, 1991
5. Reichardt VL, Okada CY, Stockerl-Goldstein KE, Bogen B, Levy R: Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma. Biol Blood Marrow Transplant 3:157, 1997
6. Bogen B, Malissen B, Haas W: Idiotype-specific T-cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur J Immunol 16, 1986
7. Lauritzsen GF, Weiss S, Dembic Z, Bogen B: Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci USA 91:5700, 1994
8. Bogen B, Munthe L, Sollien A, Hofgaard P, Omholt H, Dagnaes F, Dembic Z, Lauritzsen GF: Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies. Eur J Immunol 25:3079, 1995
9. Yamamoto H, Araki K, Bitoh S, Takata M, Takahashi S, Fujimoto S: Cytotoxic T lymphocyte clone recognizing self idiotype: Its regulatory role in antibody production. Eur J Immunol 17:719, 1987
10. Cao W, Myers-Powell BA, Braciale TJ: Recognition of an immunoglobulin VH epitope by influenza virus-specific class I major histocompatibility complex-restricted cytolytic T lymphocytes. J Exp Med 17:719, 1994
11. Bogen B: Peripheral T-cell tolerance as a tumor escape mechanism: Deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur J Immunol 26:2671, 1996
12. Yi Q, Osterborg A, Bergenbrant S, Mellstedt H, Holm G, Lefvert AK: Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood 86:3043, 1995
13. Osterborg A, Yi Q, Henriksson L, Fagerberg J, Bergenbrant S, Jeddi-Tehrani M, Ruden U, Lefvert AK, Holm G, Mellstedt H: Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type 1, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood 91:2459, 1998
14. Wen Y-J, Ling M, Bailey-Wood R, Lim SH: Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin Cancer Res 4:957, 1998
15. Kwak LW, Taub DD, Duffey PL, Bensinger WI, Bryant EM, Reynolds CW, Longo DL: Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor. Lancet 345:1016, 1995
16. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327:1209, 1992
17. Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B, Levy R: Tumor-specific idiotype vaccines in the treatment of patients with B- cell lymphoma - Long-term results of a clinical trial. Blood 89:3129, 1997
18. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335:91, 1996
19. Hart D: Dendritic cells: Unique leukocyte populations which control the primary immune response. Blood 90:3245, 1997
20. Flamand V, Sornasse T, Thielemans K, Demanet C, Bakkus M, Bazin H, Tielemans F, Leo O, Urbain J, Moser M: Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 24:605, 1994
21. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1:1297, 1995
22. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52, 1996
23. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328, 1998
24. Duhamel RC, Schur PH, Brendel K, Meezan E: pH gradient elulion of human IgG1. IgG2 and IgG4 from protein A- sepharose. J Immunol Methods 31:211, 1979
25. Campbell MJ, Esserman L, Levy R: Idiotype vaccination against murine B-cell lymphoma. Humoral and cellular responses elicited by tumor derived IgM and its molecular subunits. J Immunol 139:2825, 1987
26. Allison AC, Byars NE: An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J Immunol 110:183, 1986
27. Hsu FJ, Levy R: Preferential use of the VH4 Ig gene family by diffuse large-cell lymphoma. Blood 86:3072, 1995
28. Campbell MJ, Zelenetz AD, Levy S, Levy R: Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire. Mol Immunol 29:193, 1992
29. Syrengelas AD, Chen TT, Levy R: DNA immunization induces protective immunity against B-cell lymphoma. Nat Med 2:1038, 1996
30. Caspar CB, Levy S, Levy R: Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: Comparison of different vaccine formulations. Blood 90:3699, 1997
31. Durie BGM, Salmon SE: A clinical staging system for multiple myeloma. Cancer 36:842, 1975
32. Reichardt V, Okada C, Benike C, Long G, Engleman E, Blume K, Levy R: Idiotypic vaccination using dendritic cells for multiple myeloma patients after autologous peripheral blood stem cell transplantation. Blood 88:481a, 1996 (abstr, suppl 1)
33. Tricot GJS, Vesole D, Nelson J, Tindle S, Miller L, Cheson B, Crowley J, Barlogie B: Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients. Blood 85:588, 1995
34. Bergenbrant S, Yi Q, Osterborg A, Bjorkholm M, Osby E, Mellstedt H, Lefvert AK, Holm G: Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. Br J Haematol 92:840, 1996
35. Guillaume T, Rubinstein DB, Symann M: Immune reconstitution after autologous hematopoietic stem cell transplantation. Blood 92: 1471, 1998
36. Kwak L, Sternas LA, Jagannath S, Siegel D, Munshi NC, Barlogie B: T-cell responses elicited by immunization of multiple myeloma patients with idiotypic M-protein plus GM-CSF in remission after autologous transplantation. Blood 90:579a, 1997 (abstr, suppl 1)
37. Bohlen H, Titzer S, Christensen O, Manzke O, Wolf J, Thiele J, Diehl V, Tesch H: Dendritic cell-based idiotype vaccination in multiple myeloma. Blood 90:579a, 1997 (abstr, suppl 1)
38. Takamizawa M, Fagnoni F, Mehta-Damani A, Rivas A, Engleman EG: Cellular and molecular basis of human γδ T-cell activation. J Clin Invest 95:296, 1995
39. Mehta-Damani A, Markowicz S, Engleman EG: Generation of antigen-specific CD8+ CTLs from naive precursors. J Immunol 153:996, 1994
40. Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B, Niederwieser D, Schuler G: Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 196:137, 1996
41. Zhou LJ, Tedder TF: CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA 93:2588, 1996
42. Tarte K, Lu ZY, Fiol G, Legouffe E, Rossi JF, Klein B: Generation of virtually pure and potentially proliferating dendritic cells from non-CD34 apheresis cells from patients with multiple myeloma. Blood 90:3482, 1997